Finance > Venture Deals Database > Venture Transactions Database > Monthly Deals (All) > December 2024 VC Transactions
Ottimo Pharma

Tech Company Financing Transactions

Ottimo Pharma Funding Round

On 12/19/2024, Ottimo Pharma announced $140 million in investment from Avoro Capital Advisors, OrbiMed and Samsara BioCapital.

Transaction Overview

Company Name

Ottimo Pharma

Announced On

12/19/2024

Transaction Type

Venture Equity

Amount

$140,000,000

Round

Undisclosed

Investors

Avoro Capital Advisors (Lead Investor) (Mark Chin)

OrbiMed (Lead Investor) (Peter Thompson)

Samsara BioCapital (Lead Investor) (Srini Akkaraju)

Decheng Capital

Invus

J.P. Morgan

Janus Henderson Investors

Medicxi Ventures

RTW Investments

Proceeds Purpose

The company intends to use the funds to accelerate the lead asset, Jankistomig, a first-in-class PD1/VEGFR2 bifunctional antibody for multiple solid tumor indications, in both IV and SC forms as well as a pipeline of follow-on bifunctional assets.

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

Undisclosed
New York, NY Undisclosed
USA

Phone

Undisclosed

Website

www.ottimopharma.com

Email Address

Not Recorded

Overview

Ottimo Pharma, a NYC-based private biotech company.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

David Epstein

Browse more venture capital transactions:

Prev: 12/19/2024: Sotelix Endoscopy venture capital transaction
Next: 12/19/2024: Hauler Hero venture capital transaction

Share this article

About Our VC Transactions Data

We do our best to report on tech company VC transactions. VC investment data records reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary